Nagai SE, Hattori M, Yoshinami T, Masuda H, et al. Correction: Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2- advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study). Breast Cancer 2026 Jan 27. doi: 10.1007/s12282-025-01787.
PMID: 41591707